NurExone Biologic

We announced our Q1 2026 financial results and corporate update.

Highlights include:

✅ Technion proteomic analysis supporting our regulatory roadmap

✅ Exo-Top sublicense supporting the Company’s U.S. strategy

✅ BioXtek LOI for potential U.S. exosome manufacturing and commercialization

✅ ExoPTEN and platform IP progress in Australia and Korea

✅ Completion of a March private placement strengthening the Company’s balance sheet and supporting strategic initiatives

Read the full announcement: https://www.globenewswire.com/news-release/2026/06/01/3304336/0/en/nurexone-announces-first-quarter-2026-financial-results-and-provides-corporate-update.html

Australia has granted NurExone a patent covering the production of extracellular vesicles from stem cells, further expanding the Company’s international patent family around exosome biomanufacturing.

This follows previously announced patents in Israel and the United States, with additional applications under examination in other jurisdictions.

As NurExone advances its manufacturing capabilities and clinical-readiness strategy, expanding IP protection across key markets is another step in building long-term value.

🔗 Read more: https://www.globenewswire.com/news-release/2026/04/27/3281998/0/en/australian-patent-granted-to-nurexone-covering-stem-cell-derived-exosome-production.html

This is a really important milestone for NurExone....

Today’s strategic (non-binding) LOI between our U.S. subsidiary, Exo-Top, and BioXtek marks an important step on two critical fronts: therapeutic advancement and commercial readiness.

On the therapeutic side, the planned collaboration is expected to support U.S. GMP manufacturing and clinical supply of naïve MSC exosomes, an important building block for the future clinical development of ExoPTEN.

On the commercial side, it could open new opportunities for broader exosome manufacturing and supply in the U.S. and beyond, combining Exo-Top’s proprietary Master Cell Bank and exosome production know-how with BioXtek’s established Florida-based GMP infrastructure.

This is a meaningful step forward in building the capabilities needed to support both clinical progress and commercial opportunity.

Excited to move ahead together.
Read more: https://www.globenewswire.com/news-release/2026/04/07/3269290/0/en/NurExone-Biologic-s-U-S-Subsidiary-Exo-Top-and-Florida-Based-BioXtek-Sign-Strategic-LOI-for-Exosome-Manufacturing-and-Commercialization.html

Why did someone with experience at the highest levels of healthcare, government, and finance choose to join NurExone’s board?

A recent profile of Eyal Gabbai by Gali Weinreb in Globes offers some insight!

Gabbai, currently Chairman of Meuhedet Health Services and formerly Director General of the Prime Minister’s Office and Director of the Government Companies Authority, described NurExone co-founder Yoram Drucker as “an optimistic person, but one who does not let optimism blind him,” calling that “a rare combination among entrepreneurs.” On NurExone’s work in spinal cord injury, he added that based on the Company’s animal studies, “it seems this is not a dream. It is very hard to say no to something like that.”

Read the full (Hebrew) article here: .https://www.globes.co.il/news/article.aspx?did=1001538632

Another important step in our U.S. strategy !!

With the Exo-Top sublicense agreement, we are positioning our U.S. subsidiary to support future manufacturing, development and commercialization activities in North America 🧬

NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement Exo-Top Inc. positioned as a strategic U.S. ...

In a newly published BioProcess International e-book, exosomes are recognized as an emerging modality in biopharma!

In the article, Lior Shaltiel, PhD, describes what will be required for the field to mature for various markets, including GMP-grade manufacturing, strong CMC foundations, validated potency, and reproducible biological activity.

At NurExone, ExoPTEN is our lead focus as we advance exosome-based therapeutics for CNS injury and functional recovery, while the broader platform and manufacturing foundation we are building may also support future opportunities in aesthetics. 🔬🚀



Read the full article here:

Emerging Modalities: Clinical and Regulatory Success Scientists working in emerging modalities leverage robust quality systems & advanced analytical methods for development, clinical, and commercial success.

We will be engaging with scientific, industry, and investor audiences on how exosome-based regenerative therapies can be translated into consistent manufacturing, regulatory progress, and ultimately clinical impact at two important March forums: NANO.IL.2026 in Jerusalem and the Advanced Therapies Congress in London 🔬🧬🏭

Read more: https://www.globenewswire.com/news-release/2026/02/27/3246788/0/en/NurExone-to-Showcase-Its-Regenerative-Medicine-Platform-at-NANO-IL-2026-and-Advanced-Therapies-Congress-in-March-2026-and-Provides-Corporate-Update.html

Happy to share several internal role updates as our team and operations continue to grow 🚀 These progressions reflect expanding responsibilities, and we are very grateful for the talent and commitment behind them.

Congratulations to:

• Alina Freiman Khaikin, Ph.D. – In-Process Control Manager

• Sharon Soueid-Baumgarten – QA Manager

• Igor Paz , M.Sc – BioProcess Science & Technology Expert

• Shy Rubin – Tech Transfer Engineer

Tremendous appreciation for the entire NurExone team for the work you do every day to advance our regenerative therapies towards clinical use 👏.

During Danny Roup’s 2025 Tech Roundup panel on Israel’s Economy Channel (ערוץ 10 - ערוץ הכלכלה), Prof. Aaron Ciechanover told NurExone CEO Lior Shaltiel, PhD that NurExone is bringing hope to a field with profound human need and heavy economic costs.

We appreciate the support.



Watch a clip from the panel here:

Dr. Lior Shaltiel and Prof. Aaron Ciechanover on Channel 10 Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

A key part of the path to clinic in biotech is proving you can make the same biology, again and again 🔁🔬.

New independent proteomics data across four NurExone exosome batches shows strong batch-to-batch consistency and a differentiated protein signature versus commercial references, supporting our manufacturing and regulatory roadmap 🧬🏁.

Read more: https://www.newsfilecorp.com/release/283437/NurExone-Biologic-Advances-Manufacturing-and-Regulatory-Roadmap-with-Independent-Batch-Consistency-Results-for-Exosome-Production